Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
Normal
If you toured MDT vascular and then toured BIO in Germany, you may feel different. Ask any MD who has been to both tours.Abbott talks big with BVS yet its well known that the sent is hard to see and rumored to be stiff so in tortuous anatomy? no chance.Both orsiro(with sirolimus) and Bostons (synergy) will be the market leaders in the US come late 2015. BSX is being quiet but thier product will outdeliver Abbott by a wide marginThink of it this way, even if Bio gets 25% share in this new stent market, that one product takes a 1.2 billion dollar company to 3 billion OVERNIGHT.Wake up folks.
If you toured MDT vascular and then toured BIO in Germany, you may feel different. Ask any MD who has been to both tours.
Abbott talks big with BVS yet its well known that the sent is hard to see and rumored to be stiff so in tortuous anatomy? no chance.
Both orsiro(with sirolimus) and Bostons (synergy) will be the market leaders in the US come late 2015. BSX is being quiet but thier product will outdeliver Abbott by a wide margin
Think of it this way, even if Bio gets 25% share in this new stent market, that one product takes a 1.2 billion dollar company to 3 billion OVERNIGHT.
Wake up folks.
